01—Abstract
Summary
Summary of the 8-K filed March 17, 2026. Cited figures are marked; the original filing is the authoritative source.
Bunge Global SA's March 17, 2026 Form 8-K is a supplemental filing, not a new transaction announcement.
It provides the financial statements and pro forma information required under Item 9.01 for the acquisition of Viterra Limited, which closed on July 2, 2025. The acquisition was a stock and cash deal: Viterra shareholders received about 65.6 million Bunge shares (roughly $5.3 billiona at closing) plus about $1.9 billion in cash, and the total purchase consideration, including repayment of Viterra debt, was about $10.6 billion. Sellers, including affiliates of Glencore, CPP Investment Board and BCI, owned roughly 33% of Bunge's registered shares after closing.
The Viterra interim financials for the six months ended June 30, 2025 show revenue of $20.97 billionb (down from $22.57 billion), a gross margin of $348 million (down from $473 million), and a net loss attributable to equity holders of $196 million, versus a $71 million profit a year earlier. The net loss was driven by $223 million of interest expense and a pre-tax loss of $183 million. Viterra's balance sheet shows total borrowings of about $8.6 billion, including $3.5 billion of revolving credit facility draws.
Operating cash flow improved to $874 millionc, aided by a $1.6 billion reduction in inventories, while net debt was reduced by the use of cash and inventory liquidation. The pro forma statement of income for Bunge's year ended December 31, 2025 shows combined net sales of $89.5 billion and pro forma income from continuing operations attributable to Bunge shareholders of $650 million. Pro forma diluted EPS is $3.26, compared with $4.93 historically, reflecting the roughly 32.7 million new shares issued.
Management notes that these figures exclude expected synergies and integration costs, and that purchase price allocations remain preliminary, with final adjustments due within one year of closing. For investors, the key takeaways are the dilution from the share issuance, the higher leverage carried over from Viterra, and the expected earnings benefit from the combined platform as synergies are realized.
02—Key points
Key Highlights
- Filing is supplemental: provides Viterra's six-month 2025 interim IFRS financials (Ex. 99.1) and Bunge's pro forma FY2025 income statement (Ex. 99.2) required under Item 9.01 for the July 2, 2025 Viterra acquisition.
- Total purchase consideration of ~$10.6B: ~$5.34B in Bunge stock (65.6M shares), $1.88B cash, $3.55B repayment of Viterra debt, less $157M in settled pre-existing relationships.
- Viterra standalone H1 2025: revenue fell 7% to $20.97B, gross margin fell to $348M from $473M, and the company posted a $196M net loss attributable to equity holders versus $71M profit in H1 2024.
- Viterra's borrowings rose to ~$8.6B at June 30, 2025, with revolving credit facility draws increasing to $3.5B from $1.3B, indicating heavier reliance on short-term funding.
- Pro forma FY2025 combined net sales of $89.5B and pro forma income from continuing operations attributable to Bunge of $650M; pro forma diluted EPS of $3.26 versus $4.93 reported, reflecting ~32.7M new shares issued.
- Pro forma figures exclude synergies, cost savings and integration costs, and purchase price allocations are preliminary, with final adjustments due within one year of the acquisition date.
- Viterra's EU Oilseeds divestment (Hungary and part of Poland) is treated as discontinued operations and excluded from pro forma results; Sellers hold ~33% of Bunge's registered shares post-closing.
03—Questions
Frequently Asked Questions
Why did Bunge file this 8-K in March 2026 if the Viterra acquisition closed in July 2025?
The filing provides the financial statements and pro forma information that Item 9.01 of Form 8-K required for a significant acquisition. Bunge filed them later, and they include Viterra's interim financials for the six months ended June 30, 2025 and Bunge's pro forma income statement for FY2025. The filing does not announce a new transaction.
How much did Bunge pay for Viterra, and how was it financed?
Total purchase consideration was about $10.6B. This included about $5.34B in Bunge shares (65.6M shares), $1.88B in cash, and $3.55B to repay certain Viterra debt, less $157M for settled pre-existing relationships. The cash and debt repayment were funded with cash on hand and Bunge's existing debt instruments, including a $2.0B 3-year term loan and a $300M delayed draw term loan.
Is the Viterra acquisition dilutive to Bunge's earnings per share?
On a pro forma basis for FY2025, diluted EPS from continuing operations would have been $3.26, compared with $4.93 reported. The decline is driven mainly by the roughly 32.7M additional weighted-average shares issued. Pro forma figures exclude expected synergies and integration costs, so they do not show the earnings effect once synergies are realized.
What were Viterra's standalone financial trends before the acquisition?
In H1 2025, Viterra's revenue declined about 7% year over year to $20.97B, and gross margin fell 26% to $348M. Net loss attributable to equity holders was $196M, compared with a $71M profit in H1 2024. Interest expense of $223M and a deferred tax recovery that fell from $135M to $33M contributed to the swing. Operating cash flow improved to $874M, largely because inventories were reduced by $1.6B.
What are the main risks or open items highlighted in the filing?
The purchase price allocation is preliminary and subject to change within one year of closing. Viterra's EU Oilseeds divestment (Hungary and part of Poland) was required by European Commission approval and is excluded from pro forma continuing operations. Viterra also carries material contested tax matters, including Canada Revenue Agency reassessments for which no provision has been recorded, and total borrowings of about $8.6B at June 30, 2025 increase leverage.
04—Continue